Urine drug testing in chronic pain
- PMID: 21412368
Urine drug testing in chronic pain
Abstract
Therapeutic use, overuse, abuse, and diversion of controlled substances in managing chronic non-cancer pain continue to be an issue for physicians and patients. The challenge is to eliminate or significantly curtail abuse of controlled prescription drugs while still assuring the proper treatment of those patients. Some physicians are apprehensive regarding the use of chronic opioid therapy in chronic non-cancer pain due to a perceived lack of proven evidence, the misuse of opioids, tolerance, dependence, and hyperalgesia. However, others have criticized the underuse of opioids, resulting in the undertreatment of pain. It has been the convention that federal, state, and local governments; professional associations; as well as pharmaceutical companies, physicians, accrediting bodies, medical licensure boards, and the public all share responsibility for preventing abuse of controlled prescription drugs. To overcome the critical challenge of eliminating or significantly curtailing abuse of controlled prescription drugs and at the same time assuring the appropriate treatment for those patients who can be helped by these medications, it is crucial to practice adherence or compliance monitoring of opioid therapy. Compliance monitoring has been shown to be crucial in delivering proper opioid therapy and preserving this therapy for the future. Urine drug testing (UDT) is considered one of the mainstays of adherence monitoring in conjunction with prescription monitoring programs and other screening tools, however, UDT is associated with multiple limitations secondary to potential pitfalls related to drug metabolism, reliability of the tests, and the knowledge of the pain physician. UDT is a widely available and familiar method for monitoring opioid use in chronic pain patients. UDT can provide tools for tracking patient compliance and expose possible drug misuse and abuse. UDT is one of the major tools of adherence monitoring in the assessment of the patient's predisposition to, and patterns of, drug misuse/abuse--a vital first step towards establishing and maintaining the safe and effective use of opioid analgesics in the treatment of chronic pain. This comprehensive review provides the role of UDT in monitoring chronic opioid therapy along with reliability and accuracy, appropriate use, overuse, misuse, and abuse.
Similar articles
-
Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS).Pain Physician. 2010 Jan-Feb;13(1):E1-E22. Pain Physician. 2010. PMID: 20119473 Clinical Trial.
-
American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance.Pain Physician. 2012 Jul;15(3 Suppl):S67-116. Pain Physician. 2012. PMID: 22786449
-
Comparative evaluation of the accuracy of immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing (UDT) opioids and illicit drugs in chronic pain patients.Pain Physician. 2011 Mar-Apr;14(2):175-87. Pain Physician. 2011. PMID: 21412372 Clinical Trial.
-
Chronic pain: reducing costs through early implementation of adherence testing and recognition of opioid misuse.Postgrad Med. 2011 Nov;123(6):132-9. doi: 10.3810/pgm.2011.11.2503. Postgrad Med. 2011. PMID: 22104462 Review.
-
Monitoring opioid adherence in chronic pain patients: tools, techniques, and utility.Pain Physician. 2008 Mar;11(2 Suppl):S155-80. Pain Physician. 2008. PMID: 18443638 Review.
Cited by
-
Urine Drug Testing in Cancer Pain Management.Oncologist. 2020 Feb;25(2):99-104. doi: 10.1634/theoncologist.2019-0525. Epub 2019 Oct 11. Oncologist. 2020. PMID: 32043770 Free PMC article. Review.
-
Perceptions of Community-Dwelling Patients and Their Physicians on OxyContin® Discontinuation and the Impact on Chronic Pain Management.Pain Res Manag. 2017;2017:5402915. doi: 10.1155/2017/5402915. Epub 2017 Jan 30. Pain Res Manag. 2017. PMID: 28250709 Free PMC article.
-
Implementation of a Schedule II patient agreement for opioids and stimulants in an adult primary care practice.J Family Med Prim Care. 2017 Jan-Mar;6(1):52-57. doi: 10.4103/2249-4863.214959. J Family Med Prim Care. 2017. PMID: 29026749 Free PMC article.
-
Random urine drug testing among patients receiving opioid therapy for cancer pain.Cancer. 2021 Mar 15;127(6):968-975. doi: 10.1002/cncr.33326. Epub 2020 Nov 24. Cancer. 2021. PMID: 33231885 Free PMC article.
-
Is It Painful to Manage Chronic Pain? A Cross-Sectional Study of Physicians In-Training in a University Program.Mo Med. 2016 Jan-Feb;113(1):72-8. Mo Med. 2016. PMID: 27039496 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical